文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

屈大麻酚治疗创伤后应激障碍噩梦的随机对照试验

Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial.
PubMed 文献 · Nat Med · 2026-08-05

这项多中心、双盲、随机、安慰剂对照试验评估屈大麻酚(BX-1;Δ9-四氢大麻酚)治疗创伤后应激障碍相关噩梦的疗效与安全性。171名伴有反复噩梦的PTSD成人随机接受屈大麻酚(2.5-15 mg)或安慰剂,每晚睡前一次,持续10周。第10周时,屈大麻酚组CAPS-IV B2评分下降显著大于安慰剂组(组间差异-1.50;95%CI -2.28至-0.71;Cohen's d=0.65;P<0.001),但长期疗效与安全性仍需进一步评估。

要点

  • 屈大麻酚2.5-15 mg每晚睡前一次可显著改善PTSD相关噩梦的频率和强度。
  • 屈大麻酚组严重不良事件发生7例(8.0%),安慰剂组0例。
  • 因不良事件停药率两组相近(5.7% vs 7.2%)。

核心结论

  • 屈大麻酚可减少PTSD相关噩梦的频率和强度,但长期疗效和安全性需进一步评估。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照试验。
  • 171名伴有反复噩梦的PTSD成人随机分组,87名接受屈大麻酚,84名接受安慰剂。
  • 屈大麻酚剂量2.5-15 mg,每晚睡前一次,持续10周。

主要发现

  • 第10周CAPS-IV B2评分下降屈大麻酚组显著大于安慰剂组(组间差异-1.50;95%CI -2.28至-0.71;Cohen's d=0.65;P<0.001)。
  • 不良事件发生率屈大麻酚组78例(89.7%),安慰剂组64例(77.1%)。
  • 因不良事件停药屈大麻酚组5例(5.7%),安慰剂组6例(7.2%)。
  • 严重不良事件屈大麻酚组7例(8.0%),安慰剂组0例。

关键数值与推荐

  • 主要终点为CAPS-IV B2条目(评估噩梦频率和强度)从基线至第10周的变化。
  • 共171名患者随机分组,平均年龄37.9±12.8岁,女性占79.3%。

临床怎么用

  • 对于PTSD相关噩梦,屈大麻酚2.5-15 mg每晚睡前一次可能改善症状,但需关注严重不良事件。

局限性

  • 长期疗效和安全性需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nightmares are a hallmark of post-traumatic stress disorder (PTSD), yet pharmacological treatments remain limited. Here we conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of dronabinol (BX-1; Δ9-tetrahydrocannabinol (THC)) for PTSD-related nightmares. Adults with PTSD and recurrent nightmares were randomly assigned to receive dronabinol (2.5-15 mg) or placebo, once daily before bedtime, for 10 weeks. The primary endpoint was change from baseline to week 10 in the Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) B2 item assessing nightmare frequency and intensity. A total of 171 patients underwent randomization (mean age, 37.9 ± 12.8 years; 79.3% female), with 87 assigned to dronabinol and 84 to placebo. At week 10, reduction in CAPS-IV B2 scores was significantly greater with dronabinol than with placebo (between-group difference -1.50; 95% confidence interval -2.28 to -0.71; Cohen's d = 0.65; P < 0.001). Adverse events occurred in 78 patients (89.7%) receiving dronabinol and 64 (77.1%) receiving placebo. Treatment discontinuation due to adverse events occurred in five (5.7%) and six (7.2%) patients, respectively. Serious adverse events occurred in seven patients (8.0%) receiving dronabinol and in none receiving placebo. This trial provides evidence that dronabinol reduces the frequency and intensity of PTSD-related nightmares, although long-term efficacy and safety require further evaluation. ClinicalTrials.gov: NCT04448808 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Roepke S, Schoofs N, Priebe K, et al. Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial. Nat Med. 2026. PMID: 42557458. doi:10.1038/s41591-026-04546-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。